BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 12196356)

  • 1. Dose density and dose intensity: where does CHOP go from here?
    Portlock CS
    Ann Oncol; 2002 Sep; 13(9):1329-30. PubMed ID: 12196356
    [No Abstract]   [Full Text] [Related]  

  • 2. Randomized phase II study of biweekly CHOP and dose-escalated CHOP with prophylactic use of lenograstim (glycosylated G-CSF) in aggressive non-Hodgkin's lymphoma: Japan Clinical Oncology Group Study 9505.
    Itoh K; Ohtsu T; Fukuda H; Sasaki Y; Ogura M; Morishima Y; Chou T; Aikawa K; Uike N; Mizorogi F; Ohno T; Ikeda S; Sai T; Taniwaki M; Kawano F; Niimi M; Hotta T; Shimoyama M; Tobinai K;
    Ann Oncol; 2002 Sep; 13(9):1347-55. PubMed ID: 12196359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intensified CHOP regimen in aggressive lymphomas: maximal dose intensity and dose density of doxorubicin and cyclophosphamide.
    Balzarotti M; Spina M; Sarina B; Magagnoli M; Castagna L; Milan I; Ripa C; Latteri F; Bernardi D; Bertuzzi A; Nozza A; Roncalli M; Morenghi E; Tirelli U; Santoro A
    Ann Oncol; 2002 Sep; 13(9):1341-6. PubMed ID: 12196358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of fludarabine/mitoxantrone/dexamethasone alternating with CHOP in bulky follicular non-Hodgkin's lymphoma.
    Wilder DD; Ogden JL; Jain VK
    Clin Lymphoma; 2002 Mar; 2(4):229-37. PubMed ID: 11970762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose escalation of biweekly cyclophosphamide, doxorubicin, vincristine, and prednisolone using recombinant human granulocyte colony stimulating factor in non-Hodgkin's lymphoma.
    Tanosaki R; Okamoto S; Akatsuka N; Ishida A; Michikawa N; Masuda Y; Uchida H; Murata M; Kizaki M; Ikeda Y
    Cancer; 1994 Oct; 74(7):1939-44. PubMed ID: 7521788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New treatment strategies for aggressive lymphoma.
    Younes A
    Semin Oncol; 2004 Dec; 31(6 Suppl 15):10-3. PubMed ID: 15726533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of CHOP versus CIOP in good prognosis younger patients with histologically aggressive non-Hodgkin lymphoma.
    Burton C; Smith P; Vaughan-Hudson G; Qian W; Hoskin P; Cunningham D; Hancock B; Linch D
    Br J Haematol; 2005 Aug; 130(4):536-41. PubMed ID: 16098067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term results of a multicenter randomized, comparative trial of modified CHOP versus THP-COP versus THP-COPE regimens in elderly patients with non-Hodgkin's lymphoma.
    Mori M; Kitamura K; Masuda M; Hotta T; Miyazaki T; Miura AB; Mizoguchi H; Shibata A; Saito H; Matsuda T; Masaoka T; Harada M; Niho Y; Takaku F
    Int J Hematol; 2005 Apr; 81(3):246-54. PubMed ID: 15814336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II study of liposomal daunorubicin, in combination with cyclophosphamide, vincristine and prednisolone, in elderly patients with previously untreated aggressive non-Hodgkin lymphoma.
    Mitchell PL; Marlton P; Grigg A; Seymour JF; Hertzberg M; Enno A; Herrmann R; Bond R; Arthur C
    Leuk Lymphoma; 2008 May; 49(5):924-31. PubMed ID: 18464112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomised multicentre trial of modified CHOP versus MCOP in patients aged 65 years and over with aggressive non-Hodgkin's lymphoma.
    Bessell EM; Burton A; Haynes AP; Glaholm J; Child JA; Cullen MH; Davies JM; Smith GM; Ellis IO; Jack A; Jones EL;
    Ann Oncol; 2003 Feb; 14(2):258-67. PubMed ID: 12562653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy.
    Sonneveld P; de Ridder M; van der Lelie H; Nieuwenhuis K; Schouten H; Mulder A; van Reijswoud I; Hop W; Lowenberg B
    J Clin Oncol; 1995 Oct; 13(10):2530-9. PubMed ID: 7595704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The treatment of non-Hodgkin's lymphoma with mitoxantrone-containing regimens.
    Sonneveld P
    Semin Oncol; 1995 Feb; 22(1 Suppl 1):29-31. PubMed ID: 7863349
    [No Abstract]   [Full Text] [Related]  

  • 13. A randomized controlled trial investigating the survival benefit of dose-intensified multidrug combination chemotherapy (LSG9) for intermediate- or high-grade non-Hodgkin's lymphoma: Japan Clinical Oncology Group Study 9002.
    Kinoshita T; Hotta T; Tobinai K; Kobayashi T; Ishizuka N; Tomonaga M; Sai T; Ohno Y; Kasai M; Ogura M; Mikuni C; Toki H; Sano M; Masaki Y; Ohtsu T; Matsuno Y; Takenaka T; Shirakawa S; Shimoyama M;
    Int J Hematol; 2004 Nov; 80(4):341-50. PubMed ID: 15615259
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential of chromosomal and matrix-based comparative genomic hybridization for molecular diagnostics in lymphomas.
    Wessendorf S; Lichter P; Schwänen C; Fritz B; Baudis M; Walenta K; Kloess M; Döhner H; Bentz M
    Ann Hematol; 2001; 80 Suppl 3():B35-7. PubMed ID: 11757703
    [No Abstract]   [Full Text] [Related]  

  • 15. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.
    Cunningham D; Hawkes EA; Jack A; Qian W; Smith P; Mouncey P; Pocock C; Ardeshna KM; Radford JA; McMillan A; Davies J; Turner D; Kruger A; Johnson P; Gambell J; Linch D
    Lancet; 2013 May; 381(9880):1817-26. PubMed ID: 23615461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intensified CHOP in non-Hodgkin's lymphoma: what we know and what we need to know.
    Santoro A; Balzarotti M; Castagna L
    Ann Oncol; 1999 Aug; 10(8):875-6. PubMed ID: 10509145
    [No Abstract]   [Full Text] [Related]  

  • 17. Phase II study of infusional chemotherapy with doxorubicin, vincristine and etoposide plus cyclophosphamide and prednisone (I-CHOPE) in resistant diffuse aggressive non-Hodgkin's lymphoma: CALGB 9255. Cancer and Leukemia Group B.
    Lichtman SM; Niedzwiecki D; Barcos M; Carlisle TL; Cooper MR; Johnson JL; Peterson BA
    Ann Oncol; 2000 Sep; 11(9):1141-6. PubMed ID: 11061609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biweekly CHOP or THP-COP regimens in the treatment of newly diagnosed aggressive non-Hodgkin's lymphoma. A comparison of doxorubicin and pirarubicin: a randomized phase II study.
    Tsurumi H; Yamada T; Sawada M; Kasahara S; Kanemura N; Kojima Y; Fukuno K; Hara T; Saio M; Takahashi T; Oyama M; Ozawa K; Takami T; Moriwaki H
    J Cancer Res Clin Oncol; 2004 Feb; 130(2):107-13. PubMed ID: 14648210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aggressive non-Hodgkin's lymphoma in elderly patients: where to go from here?
    Obrist R
    Eur J Cancer; 1994; 30A(9):1213-4. PubMed ID: 7999399
    [No Abstract]   [Full Text] [Related]  

  • 20. Dose-escalation of CHOP in non-Hodgkin's lymphoma.
    Santoro A; Balzarotti M; Tondini C; Zanini M; Giardini R; Latteri F; Rampinelli I; Bufalino R
    Ann Oncol; 1999 May; 10(5):519-25. PubMed ID: 10416000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.